{"id":28161,"date":"2024-05-28T17:59:02","date_gmt":"2024-05-28T12:29:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28161"},"modified":"2024-05-28T17:59:06","modified_gmt":"2024-05-28T12:29:06","slug":"pharma-news-for-astrazeneca-biogen-altrubio-gsk","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk","title":{"rendered":"AstraZeneca\u2019s Tropion-Lung01 Phase III Trial Positive Outcomes; Biogen\u2019s LEQEMBI South Korea Approval; AltruBio\u2019s $225M Series B Funding; GSK&#8217;s Depemokimab Positive Phase III Severe Asthma Results; Roche\u2019s Inavolisib FDA Breakthrough Therapy Designation"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e20ad85fde\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e20ad85fde\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk\/#The_Tropion-Lung01_Phase_III_Trial_Reveals_that_Datopotamab_Deruxtecan_Significantly_Enhanced_Overall_Survival_in_Advanced_Nonsquamous_NSCLC_Patients_Compared_to_Chemotherapy\" >The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk\/#Biogens_LEQEMBI_Gains_Approval_in_South_Korea_for_Alzheimers_Disease\" >Biogen\u2019s LEQEMBI Gains Approval in South Korea for Alzheimer&#8217;s Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk\/#AltruBio_Raises_225M_in_Oversubscribed_Series_B_to_Propel_Immune_Checkpoint_Enhancer_Program\" >AltruBio Raises $225M in Oversubscribed Series B to Propel Immune Checkpoint Enhancer Program<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk\/#GSKs_Depemokimab_Shows_Promising_Results_in_Phase_III_Severe_Asthma_Studies\" >GSK&#8217;s Depemokimab Shows Promising Results in Phase III Severe Asthma Studies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk\/#Roches_Inavolisib_Receives_FDA_Breakthrough_Therapy_Designation_for_Advanced_HR_HER2-_Breast_Cancer_with_PIK3CA_Mutation\" >Roche\u2019s Inavolisib Receives FDA Breakthrough Therapy Designation for Advanced HR+ HER2- Breast Cancer with PIK3CA Mutation<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-the-tropion-lung01-phase-iii-trial-reveals-that-datopotamab-deruxtecan-significantly-enhanced-overall-survival-in-advanced-nonsquamous-nsclc-patients-compared-to-chemotherapy\"><span class=\"ez-toc-section\" id=\"The_Tropion-Lung01_Phase_III_Trial_Reveals_that_Datopotamab_Deruxtecan_Significantly_Enhanced_Overall_Survival_in_Advanced_Nonsquamous_NSCLC_Patients_Compared_to_Chemotherapy\"><\/span>The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The high-level overall survival (OS) results from the <strong>TROPION-Lung01 Phase III trial<\/strong>, which had previously met the dual primary endpoint of progression-free survival (PFS), showed that datopotamab deruxtecan (Dato-DXd) was numerically favored over docetaxel in the overall population of <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-non-small-cell-lung-cancer-market\">patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/a> who had received at least one prior line of therapy. However, the survival results did not achieve statistical significance in the overall trial population. In the prespecified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan demonstrated a clinically meaningful improvement in OS compared to docetaxel, the current standard-of-care chemotherapy.<\/p>\n\n\n\n<p>The final analysis of overall survival (OS) is based on the positive progression-free survival (PFS) results presented at the <a href=\"https:\/\/www.delveinsight.com\/esmo-conference-2023\"><strong>2023 European Society for Medical Oncology Congress<\/strong><\/a>. These results demonstrated that datopotamab deruxtecan significantly improved PFS in the overall trial population and provided a clinically meaningful PFS benefit for patients with nonsquamous NSCLC. In the TROPION-Lung01 study, patient enrollment by tumor histology was balanced across treatment arms and reflected real-world incidence, with approximately 75% of patients having nonsquamous NSCLC.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Susan Galbraith, Executive Vice President of Oncology R&amp;D at AstraZeneca, stated: &#8220;Datopotamab deruxtecan stands out as the only investigational treatment to demonstrate a significant survival benefit for patients with previously treated nonsquamous non-small cell lung cancer compared to docetaxel, a standard that has remained unbeaten in the post-targeted treatment and post-immunotherapy context. These findings highlight the potential of datopotamab deruxtecan to supplant traditional chemotherapy in this advanced treatment setting and bolster our confidence in the ongoing trials assessing this therapy for first-line lung cancer.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd <a href=\"https:\/\/www.delveinsight.com\/report-store\/antibody-drug-conjugate-market\">antibody-drug conjugate<\/a> developed by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. Information regarding its efficacy will be shared at an upcoming medical conference, bolstering its regulatory submissions worldwide, notably in the US and EU, for treating adult patients with locally advanced or metastatic nonsquamous NSCLC who have previously undergone systemic therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-biogen-s-leqembi-gains-approval-in-south-korea-for-alzheimer-s-disease\"><span class=\"ez-toc-section\" id=\"Biogens_LEQEMBI_Gains_Approval_in_South_Korea_for_Alzheimers_Disease\"><\/span>Biogen\u2019s LEQEMBI Gains Approval in South Korea for Alzheimer&#8217;s Disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Eisai Co., Ltd. and Biogen Inc.<\/strong> declared that South Korea&#8217;s Ministry of Food and Drug Safety (MFDS) has given the green light to &#8220;<strong>LEQEMBI\u00ae<\/strong>&#8221; <strong>(lecanemab)<\/strong>, a humanized monoclonal antibody targeting aggregated amyloid-beta (A\u03b2), for treating mild cognitive impairment or mild <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s disease in adults<\/a>.<\/p>\n\n\n\n<p>LEQEMBI exhibits specific affinity towards soluble A\u03b2 aggregates (protofibrils) and insoluble A\u03b2 aggregates (fibrils), which are significant constituents of A\u03b2 plaques observed in Alzheimer&#8217;s disease. Consequently, it diminishes the presence of both A\u03b2 protofibrils and A\u03b2 plaques within the brain. Notably, LEQEMBI stands as the pioneer treatment authorized to mitigate disease advancement and alleviate cognitive and functional deterioration via this pathway. South Korea joins the ranks as the fourth nation to endorse its usage, after approvals secured in the U.S., Japan, and China.<\/p>\n\n\n\n<p>In 2021, South Korea had around <strong>900,000<\/strong> individuals affected by dementia, with approximately one out of every ten people over 65 experiencing dementia and one out of every five experiencing mild cognitive impairment (MCI). The average yearly expenses for nursing care and medical treatment per dementia patient were estimated at <strong>21.1 million<\/strong> KRW, while those with severe dementia incurred costs of around <strong>33.1 million<\/strong> KRW.<\/p>\n\n\n\n<p>Eisai takes the helm in overseeing the global development and regulatory processes for LEQEMBI, with both Eisai and Biogen collaborating on its commercialization. Eisai holds the ultimate decision-making power. In South Korea, distribution and information provision for the product will be handled by Eisai Korea Inc. Eisai is dedicated to collaborating with healthcare professionals and other stakeholders to advance early diagnosis and <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">treatment of Alzheimer\u2019s disease<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-altrubio-raises-225m-in-oversubscribed-series-b-to-propel-immune-checkpoint-enhancer-program\"><span class=\"ez-toc-section\" id=\"AltruBio_Raises_225M_in_Oversubscribed_Series_B_to_Propel_Immune_Checkpoint_Enhancer_Program\"><\/span>AltruBio Raises $225M in Oversubscribed Series B to Propel Immune Checkpoint Enhancer Program<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AltruBio Inc. <\/strong>revealed that its Series B financing round, which was in high demand, has secured funding totaling <strong>$225 million<\/strong>. The company intends to allocate these funds towards furthering the clinical progress of its innovative immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. Specifically, the financing will support the advancement of ongoing and forthcoming Phase II clinical trials focusing on <a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market\">ulcerative colitis<\/a>, among other immunological disorders where the effectiveness of the mechanism has been confirmed through clinical validation.<\/p>\n\n\n\n<p>The financing was led by BVF Partners LP with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital, and Delos Capital, as well as existing investors aMoon Fund and Blackstone Multi-Asset Investing, with other new and existing investors joining the syndicate.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Judy Chou, President and CEO of AltruBio, expressed gratitude for the esteemed new investors joining their ranks, highlighting how their support aligns with the existing investor base&#8217;s caliber. She emphasized the validation this collective backing provides for their program and mission of advancing durable biologic therapies for autoimmune disease patients. With this substantial investment, they move closer to advancing ALTB-268, a pioneering immune checkpoint enhancer, through Phase 2a biomarker study and initiating Phase 2b, with the potential to broaden its application beyond ulcerative colitis. Dr. Chou noted that their capable team and this significant funding position them to expedite efforts and deliver innovative treatments to those in need.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The pioneering ICE agonist antibody, <strong>ALTB-268<\/strong>, developed by the Company, is undergoing Phase IIa exploratory biomarker research in individuals with biologic refractory UC. The primary objective is to assess clinical remission based on a modified Mayo score, with results expected in the first half of 2025. Subsequently, the Company intends to launch a global Phase IIb trial, randomized and placebo-controlled, targeting clinical remission in patients with moderately to severely active UC, including those who have undergone advanced therapies and those who are treatment-naive. The outcome of this trial is projected to be available in the second half of 2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gsk-s-depemokimab-shows-promising-results-in-phase-iii-severe-asthma-studies\"><span class=\"ez-toc-section\" id=\"GSKs_Depemokimab_Shows_Promising_Results_in_Phase_III_Severe_Asthma_Studies\"><\/span>GSK&#8217;s Depemokimab Shows Promising Results in Phase III Severe Asthma Studies<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>GSK plc<\/strong> reported positive top-line results from the <strong>phase III clinical trials SWIFT-1 and SWIFT-2,<\/strong> which evaluated the effectiveness and safety of <strong>depemokimab <\/strong>compared to a placebo in <a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-asthma-market\">adults and adolescents with severe asthma<\/a> characterized by type 2 inflammation and elevated blood eosinophil levels. Both SWIFT-1 and SWIFT-2 achieved their primary goals, showing a reduction in the annual rate of clinically significant exacerbations (asthma attacks) over 52 weeks. In both trials, the frequency and severity of treatment-emergent adverse events were similar between the depemokimab and placebo groups. Further analysis of the data is currently underway.<\/p>\n\n\n\n<p>Depemokimab is the pioneering ultra-long-acting biologic undergoing phase III trials, exhibiting high binding affinity and potency for interleukin-5 (IL-5), which allows for six-month dosing intervals in severe asthma patients. IL-5 is a crucial cytokine involved in type 2 inflammation, often marked by elevated blood eosinophil levels. This type of inflammation is the primary cause of over 80% of severe asthma cases and can result in unpredictable flare-ups.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Kaivan Khavandi, SVP, Global Head of Respiratory\/Immunology R&amp;D, stated: &#8220;These findings contribute to the existing evidence that targeting IL-5 inhibition is crucial in decreasing type 2 inflammation, which leads to severe asthma flare-ups. Depemokimab might provide sustained pathway inhibition, requiring only two injections annually. This is significant as studies indicate that 73% of physicians believe longer dosing intervals would benefit patients who frequently manage multiple treatments.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Expertise in respiratory diseases and IL-5 science has guided the ongoing evidence-generation program assessing the effects of six-month dosing of sustained IL-5 inhibition in <a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-asthma-market\">patients with severe asthma<\/a> who have achieved clinical remission. The comprehensive results of the SWIFT-1 and SWIFT-2 studies will be presented at an upcoming scientific congress and will aid in regulatory submissions to health authorities globally. Depemokimab is not yet approved in any country.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-s-inavolisib-receives-fda-breakthrough-therapy-designation-for-advanced-hr-her2-breast-cancer-with-pik3ca-mutation\"><span class=\"ez-toc-section\" id=\"Roches_Inavolisib_Receives_FDA_Breakthrough_Therapy_Designation_for_Advanced_HR_HER2-_Breast_Cancer_with_PIK3CA_Mutation\"><\/span>Roche\u2019s Inavolisib Receives FDA Breakthrough Therapy Designation for Advanced HR+ HER2- Breast Cancer with PIK3CA Mutation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Roche <\/strong>has revealed that the FDA has awarded <strong>Breakthrough Therapy Designation<\/strong> to inavolisib, an experimental oral treatment when used alongside <strong>palbociclib (Ibrance\u00ae)<\/strong> and fulvestrant. This combination is intended for adult patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or <a href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her2-negative-breast-cancer-market-insights\">metastatic breast cancer<\/a>, who have experienced a recurrence during or within 12 months after finishing adjuvant endocrine therapy.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are delighted that the FDA has awarded Breakthrough Therapy Designation to inavolisib, acknowledging the significant clinical benefits seen with this treatment,\u201d stated Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development at Roche. \u201cThis promising inavolisib-based therapy has the potential to revolutionize the PI3K inhibitor class and may become the standard first-line treatment for this patient group.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA&#8217;s decision is based on the positive results from the <strong>Phase III INAVO120 trial<\/strong>, which demonstrated that the inavolisib-based treatment regimen reduced the risk of disease progression or death (progression-free survival) by 57% compared to the combination of palbociclib and fulvestrant alone (15.0 months vs. 7.3 months; hazard ratio [HR]=0.43, 95% CI: 0.32-0.59, p&lt;0.0001). Although the overall survival (OS) data are still immature, there is a clear positive trend observed (stratified HR=0.64, 95% CI: 0.43-0.97, p=0.0338 with a boundary of 0.0098). Follow-up for overall survival will continue until the next analysis. These findings highlight the potential of the inavolisib-based regimen to benefit patients with PIK3CA-mutated locally advanced or metastatic breast cancer.<\/p>\n\n\n\n<p>Inavolisib is presently undergoing evaluation in three company-sponsored Phase III clinical trials (<strong>INAVO120, INAVO121, INAVO122<\/strong>) for PIK3CA-mutated locally advanced or metastatic breast cancer, in various combination therapies. We are also exploring opportunities to expand our clinical development program to address unmet patient needs in different tumor types across oncology.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy The high-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which had previously met the dual primary endpoint of progression-free survival (PFS), showed that datopotamab deruxtecan (Dato-DXd) was numerically favored over docetaxel [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28167,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[72,204,22090,704,349,3879,420,1111,12558,639,5789,19719,19720,16410],"industry":[17225],"therapeutic_areas":[17239,17245,17228],"class_list":["post-28161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-delveinsight","tag-esmo-2023","tag-fda","tag-latest-pharma-news","tag-metastatic-breast-cancer","tag-news","tag-nsclc","tag-nsclc-market","tag-pharma-news","tag-recent-pharma-news","tag-severe-asthma","tag-severe-asthma-market","tag-ulcerative-colitis","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | AstraZeneca, Biogen, AltruBio, GSK<\/title>\n<meta name=\"description\" content=\"AstraZeneca\u2019s Tropion-Lung01 Phase III; Biogen\u2019s LEQEMBI; AltruBio\u2019s Series B Funding; GSK&#039;s Depemokimab; Roche\u2019s Inavolisib\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | AstraZeneca, Biogen, AltruBio, GSK\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca\u2019s Tropion-Lung01 Phase III; Biogen\u2019s LEQEMBI; AltruBio\u2019s Series B Funding; GSK&#039;s Depemokimab; Roche\u2019s Inavolisib\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-28T12:29:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-28T12:29:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/28175827\/pharma-news-for-astrazeneca-biogen-altrubio-gsk.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | AstraZeneca, Biogen, AltruBio, GSK","description":"AstraZeneca\u2019s Tropion-Lung01 Phase III; Biogen\u2019s LEQEMBI; AltruBio\u2019s Series B Funding; GSK's Depemokimab; Roche\u2019s Inavolisib","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk","og_locale":"en_US","og_type":"article","og_title":"Pharma News | AstraZeneca, Biogen, AltruBio, GSK","og_description":"AstraZeneca\u2019s Tropion-Lung01 Phase III; Biogen\u2019s LEQEMBI; AltruBio\u2019s Series B Funding; GSK's Depemokimab; Roche\u2019s Inavolisib","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-05-28T12:29:02+00:00","article_modified_time":"2024-05-28T12:29:06+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/28175827\/pharma-news-for-astrazeneca-biogen-altrubio-gsk.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk","name":"Pharma News | AstraZeneca, Biogen, AltruBio, GSK","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/28175827\/pharma-news-for-astrazeneca-biogen-altrubio-gsk.png","datePublished":"2024-05-28T12:29:02+00:00","dateModified":"2024-05-28T12:29:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"AstraZeneca\u2019s Tropion-Lung01 Phase III; Biogen\u2019s LEQEMBI; AltruBio\u2019s Series B Funding; GSK's Depemokimab; Roche\u2019s Inavolisib","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astrazeneca-biogen-altrubio-gsk#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/28175827\/pharma-news-for-astrazeneca-biogen-altrubio-gsk.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/28175827\/pharma-news-for-astrazeneca-biogen-altrubio-gsk.png","width":772,"height":482,"caption":"pharma-news-for-astrazeneca-biogen-altrubio-gsk"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/28175827\/pharma-news-for-astrazeneca-biogen-altrubio-gsk-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ESMO 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">metastatic breast cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">severe asthma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">severe asthma market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ulcerative colitis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">ESMO 2023<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">metastatic breast cancer<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">NSCLC Market<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">severe asthma<\/span>","<span class=\"advgb-post-tax-term\">severe asthma market<\/span>","<span class=\"advgb-post-tax-term\">Ulcerative colitis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 28, 2024","modified":"Updated on May 28, 2024"},"absolute_dates_time":{"created":"Posted on May 28, 2024 5:59 pm","modified":"Updated on May 28, 2024 5:59 pm"},"featured_img_caption":"pharma-news-for-astrazeneca-biogen-altrubio-gsk","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28161"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28161\/revisions"}],"predecessor-version":[{"id":28162,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28161\/revisions\/28162"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28167"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28161"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28161"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}